Holen Sie sich die Stockscreener-App
231.20
3.54%
7.91
Handel nachbörslich:
233.56
2.36
+1.02%
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Canada
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism - TipRanks
Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits - Stock Titan
Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Ascendis Pharma completes Phase 3 PaTHway Trial - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
(ASND) Risk Channels and Responsive Allocation - Stock Traders Daily
Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years - Quiver Quantitative
Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D - Stock Titan
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock. - Pluang
Why Is Ascendis Pharma Stock Gaining Friday? - Benzinga
Ascendis boasts of long-term Yorvipath data for hypoparathyroidism - MSN
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism - TipRanks
Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND) - Stock Titan
Ascendis reports 5-year data for hypoparathyroidism drug - Investing.com UK
Ascendis reports 5-year data for hypoparathyroidism drug By Investing.com - Investing.com Australia
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Moomoo
5-year trial: drug frees most hypoparathyroidism patients from supplements - Stock Titan
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic - GlobeNewswire
Ascendis Pharma Named Among Top Profitable Growth Stocks: Market Recognition BuildsMid-Term Outlook - newsline.com
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share By Investing.com - Investing.com South Africa
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan - TipRanks
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share - Investing.com
[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC FilingForm 6-K - Stock Titan
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Yahoo Finance
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case By Investing.com - Investing.com Australia
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case - Investing.com
10 Most Profitable Growth Stocks to Buy - Insider Monkey
Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026 - Quiver Quantitative
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewswire Inc.
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness - simplywall.st
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Yahoo Finance
Why Ascendis Pharma Stock Is Sinking Today - TipRanks
Ascendis Pharma A/S (ASND) Stock Analysis: Unlocking a 40% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Capital International Ltd. CA Sells 4,811 Shares of Ascendis Pharma A/S $ASND - MarketBeat
ASND Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside - TradingView
TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND - MarketBeat
The Option Play Of The Week (NASDAQ:ASND) - Seeking Alpha
Westfield Capital Management Co. LP Cuts Stake in Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma reports trial data on achondroplasia treatment - Investing.com
Ascendis Pharma’s YUVIWEL gains orphan drug exclusivity in U.S. - Investing.com
ASND Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Falls 1%Estimate Dispersion - newsline.com
Insider Buying: Scott Smith Acquires Additional Shares of Ascend - GuruFocus
Ascendis Pharma A/S - MLQ.ai
Insider Buying: Scott Smith Acquires Additional Shares of Ascendis Pharma AS (ASND) - GuruFocus
Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy - Stock Titan
AlphaCentric Life Sciences and Healthcare Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
(ASND) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Insider Buying: Jean Bienaime Acquires Additional Shares of Asce - GuruFocus
Ascendis Pharma (ASND) director adds 500 shares in open-market buys - Stock Titan
Ascendis Pharma (ASND) CFO makes open-market buy of 250 shares - Stock Titan
Ascendis Pharma (NASDAQ: ASND) CFO details shares, RSUs and warrant stakes - Stock Titan
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - AOL.com
Ascendis Pharma A/S (ASND) Stock Analysis: A 33% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout - TipRanks
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):